In 2011, AstraZeneca performed a proof of principal clinical trial on 54 subjects with BRCA1 or BRCA2 mutations with advanced breast cancer that were treated with PARP inhibitor olaparib [107]. Here, BRCA1 is linked to breast carcinoma.